🇺🇸 FDA

Company profile · Sponsor

ProQR

ProQR Therapeutics N.V.

PRQR · NYSE pharma LEIDEN, USA
Pipeline
6
Drugs
0
Patents
8

Quick answer

ProQR (PRQR) is a pharma company. headquartered in LEIDEN, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker PRQR
Exchange NYSE
Company type pharma
Headquarters LEIDEN, USA
SEC CIK 0001612940

Pipeline (6)

Search pipeline →

  1. sepofarsen

    ProQR

    Leber Congenital Amaurosis 10

    phase 3 small molecule active

    2 trials

  2. QR-010

    ProQR

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  3. QR-1123

    ProQR

    Autosomal Dominant Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial

  4. QR-421a

    ProQR

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  5. A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS

    ProQR

    Cholestatic liver disease

    phase 1 other active

    1 trial

  6. QR-504a

    ProQR

    Fuchs Endothelial Corneal Dystrophy

    phase 1 small molecule terminated

    1 trial

Patents (8)

Search patents →

  1. US 12275937

    Stereospecific linkages in RNA editing oligonucleotides

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12203072

    Chemically modified single-stranded rna-editing oligonucleotides

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12180471

    Antisense oligonucleotides for the treatment of Stargardt disease

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12018257

    Single-stranded RNA-editing oligonucleotides

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11920132

    Oligonucleotide therapy for Leber congenital amaurosis

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11851656

    Chemically modified single-stranded RNA-editing oligonucleotides

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11649454

    Single-stranded RNA-editing oligonucleotides

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11479771

    Antisense oligonucleotides for the treatment of eye disease

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ProQR?

ProQR (PRQR) is a pharma company. headquartered in LEIDEN, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does ProQR sponsor?

We track 6 ClinicalTrials.gov-linked programs for ProQR, including sepofarsen and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ProQR company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.